Announcements
On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 9 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 22, Issue 9, 02 March 2017
Letter
O'Donnell and Igoe: Letter to the editor: Increasing proportion of new HIV diagnoses in Ireland previously diagnosed elsewhere – potential impact on estimating incidence

+ Author affiliations


Citation style for this article: O'Donnell K, Igoe D. Letter to the editor: Increasing proportion of new HIV diagnoses in Ireland previously diagnosed elsewhere – potential impact on estimating incidence. Euro Surveill. 2017;22(9):pii=30472. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.9.30472

Received:17 February 2017; Accepted:27 February 2017

To the editor: In a recent issue of Eurosurveillance, Pharris et al. presented a very interesting study which estimated the HIV incidence and number of undiagnosed people living with HIV in the European Union/European Economic Area (EU/EEA) [1]. The ‘Incidence Method’ used was a CD4 cell count-based back-calculation method [2].

The use of CD4 counts raises important issues for HIV surveillance and interpretation of findings. The Irish surveillance system, for example, includes all persons newly diagnosed with HIV in Ireland, even if previously diagnosed elsewhere. An increasing proportion of newly-diagnosed HIV cases have previously been diagnosed HIV-positive in another country before arrival in Ireland, and have been receiving antiretroviral therapy (ART). In 2015, 27% (129/485) of newly-diagnosed HIV cases had a previous HIV diagnosis in another country, up from a range of 14%–18% for the years 2011 to 2014 [3]. By risk group, heterosexuals were the group with the highest proportion previously diagnosed HIV-positive (35%, 45/130), followed by men who have sex with men (MSM) (29%, 72/247) and people who inject drugs (PWID) (10%, 5/49). The majority (79%, 102/129) of those with a previous HIV diagnosis, transferred their HIV care to Ireland and 63% (81/129) had been receiving ART before arrival in Ireland.

We found that when looking at stage of infection, as per CD4 cell counts at diagnosis, the contribution of people who were previously diagnosed HIV-positive and on treatment can make a considerable difference to the findings. Of those newly diagnosed with HIV in Ireland in 2015, 45% (n=161) were late presenters (CD4 cell count at diagnosis less than 350 cells/µl or an AIDS defining illness at diagnosis), where information on CD4 count or AIDS defining illness at diagnosis was available (74%, 357/485). However, confining the analysis to those who were not reported to have a previous diagnosis abroad, 52% (126/243) presented late. Understandably, the proportion of people presenting late among those who had a previous HIV diagnosis was much lower (31%, 35/114). Consequently, the use of CD4 count data to estimate HIV incidence should be carefully considered in countries where surveillance data includes a significant proportion of people who have been previously diagnosed with HIV in another country, who have previously received ART, and who have transferred their care to Ireland.

Another issue for consideration is the best way to present HIV surveillance data to reflect the increasing proportion of people with prior HIV infection. This will be important in order to accurately measure the impact of HIV prevention strategies within countries and at European level. Due to increased access to testing and treatment worldwide and the mobility of populations in general, this number is likely to remain high. In our opinion this should be an important consideration for surveillance of HIV at both national and European levels.


Conflict of interest

None declared.

Authors’ contributions

Both authors composed the letter.


References

  1. Pharris A, Quinten C, Noori T, Amato-Gauci AJ, van Sighem A, ECDC HIV/AIDS Surveillance and Dublin Declaration Monitoring Networks. Estimating HIV incidence and number of undiagnosed individuals living with HIV in the European Union/European Economic Area, 2015.Euro Surveill. 2016;21(48):30417. DOI: 10.2807/1560-7917.ES.2016.21.48.30417 PMID: 27934585

  2. van Sighem A, Nakagawa F, De Angelis D, Quinten C, Bezemer D, de Coul EO,  et al.  Estimating HIV incidence, Time to Diagnosis, and the undiagnosed HIV epidemic using routine surveillance data. Epidemiology. 2015;26(5):653-60. DOI: 10.1097/EDE.0000000000000324 PMID: 26214334

  3. Health Service Executive (HSE). Health Protection Surveillance Centre (HPSC). HIV in Ireland, 2015. Dublin: HPSC; 5 Oct 2016. Available from: http://www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/SurveillanceReports/File,15862,en.pdf



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.